Although satralizumab's SatraGO-1 trial failed to meet its primary efficacy endpoint at week 24, satralizumab received approval based on efficacy results from satralizumab's SatraGO-2

From the articleSatralizumab Approved for Thyroid Eye DiseaseAlso in First At-Home Thyroid Eye Disease Shot Approved